{"canonical":"https://abierto.us/vendors/auravax-therapeutics-inc-pan3zk2ylal2","key":"PAN3ZK2YLAL2","name":"AURAVAX THERAPEUTICS, INC.","uei":"PAN3ZK2YLAL2","city":"HOUSTON","state":"TX","awards":1,"obligated":"749999.00","notices_won":0,"top_agency_name":"Office of Assistant Secretary for Preparedness and Response","top_naics":"541714","cage":"969E2","parent_name":"AURAVAX THERAPEUTICS, INC.","also_known_as":[],"country":"USA","actions":4,"first_action":"2024-09-16","last_action":"2025-12-19","breakdowns":{"naics":[{"key":"541714","name":null,"awards":1,"obligated":"749999.00"}],"places":[{"key":"TX","name":null,"awards":1,"obligated":"749999.00"}],"agencies":[{"key":"7505","name":"Office of Assistant Secretary for Preparedness and Response","awards":1,"obligated":"749999.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":1,"obligated":"749999.00"}],"competition":[{"key":"FULL AND OPEN COMPETITION","name":null,"awards":1,"obligated":"749999.00"}],"product_service_codes":[{"key":"AN14","name":null,"awards":1,"obligated":"749999.00"}]},"awards_list":[{"award_key":"CONT_AWD_75A50124C00054_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50124C00054_7505_-NONE-_-NONE-/","piid":"75A50124C00054","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"PAN3ZK2YLAL2","recipient_name":"AURAVAX THERAPEUTICS, INC.","recipient_uei":"PAN3ZK2YLAL2","recipient_cage":"969E2","recipient_city":"HOUSTON","recipient_state":"TX","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-09-16","last_action_date":"2025-12-19","actions":4,"obligated":"749999.00","current_total_value":"749999.00","potential_total_value":"749999.00","naics":"541714","psc":"AN14","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":1,"description":"THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":1,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}